SCHEMBL6776320

SCHEMBL6776320

CCCCCc1cc(O)c2c3c(C(N)=O)cccc3n(Cc3cccc(Cc4ccccc4)c3)c2c1

nearest known ligand 0.41

Predicted protein targets (top 10)

geneUniProtsupporting neighboursconfidence
PPARG P37231 6/20 0.41
CNR1 P21554 3/20 0.39
CNR2 P34972 3/20 0.39
PLA2G2A P14555 4/20 0.38
PLA2G10 O15496 1/20 0.37
PPARA Q07869 1/20 0.37
KLK1 P06870 1/20 0.36
GPR55 Q9Y2T6 1/20 0.36
PLK1 P53350 1/20 0.35
KAT8 Q9H7Z6 2/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5212214 0.93 PPARG (0.46) PPARGPLA2G2APPARAKAT8
SCHEMBL6781319 0.91 PPARG (0.42) PPARGCNR1CNR2PLA2G2APPARA
SCHEMBL6778298 0.90 CNR1 (0.43) PPARGCNR1CNR2PLA2G2APPARA
SCHEMBL6777282 0.89 PLA2G2A (0.41) PLA2G2APLA2G10KLK1
SCHEMBL6888047 0.89 CNR1 (0.38) PPARGCNR1CNR2PPARAGPR55
SCHEMBL6776640 0.89 CETP (0.41) PPARGPLA2G2APPARA
SCHEMBL6770304 0.89 CNR1 (0.42) PPARGCNR1CNR2PLA2G2APPARA
SCHEMBL6775871 0.88 LMNA (0.40) PPARGCNR2PLA2G2APPARA
SCHEMBL6773827 0.88 PPARG (0.39) PPARGPLA2G2APPARA
SCHEMBL6774931 0.88 PLA2G2A (0.48) PPARGCNR1CNR2PLA2G2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6713645-B1 INHIBITING SPLA2 MEDIATED RELEASE OF FATTY ACIDS FOR TREATMENT OF CONDITIONS SUCH AS SEPTIC SHOCK ELI LILLY AND COMPANY 2004-03-30 US disclosed
US-6177440-B1 THERAPY FOR SEPSIS SHOCK; PHOSPHOLIPASE INHBITOR ELI LILLY AND COMPANY 2001-01-23 US disclosed
EP-0952149-A2 Substituted carbazoles, process for their preparation and their use as sPLA2 inhibitiors ELI LILLY AND COMPANY (US) 1999-10-27 EP disclosed